Top Markets
#1 Black Phoenix Black Phoenix +167.48%
#2 Islamic Coin Islamic Coin +158.25%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +38.72%
#5 Cryptopia Cryptopia +20.92%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.45%
#7 Test Test +17.66%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +12.43%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.97%
#10 stake.link stake.link +9.42%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Classificação em ações #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Preço da ação
$0.0005
Última sincronização: 2026-08-11
Valor de mercado
$10.28K
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar VIA Pharmaceuticals, Inc. (VIAP)

Categoria

Healthcare
Receita da VIA Pharmaceuticals, Inc. (VIAP)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da VIA Pharmaceuticals, Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da VIA Pharmaceuticals, Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US